288 related articles for article (PubMed ID: 35107987)
1. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
Conte G; Costabile G; Baldassi D; Rondelli V; Bassi R; Colombo D; Linardos G; Fiscarelli EV; Sorrentino R; Miro A; Quaglia F; Brocca P; d'Angelo I; Merkel OM; Ungaro F
ACS Appl Mater Interfaces; 2022 Feb; 14(6):7565-7578. PubMed ID: 35107987
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Lipid/Polymer Nanoparticles for Pulmonary Delivery of siRNA: Development and Fate Upon In Vitro Deposition on the Human Epithelial Airway Barrier.
d'Angelo I; Costabile G; Durantie E; Brocca P; Rondelli V; Russo A; Russo G; Miro A; Quaglia F; Petri-Fink A; Rothen-Rutishauser B; Ungaro F
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):170-181. PubMed ID: 29035132
[TBL] [Abstract][Full Text] [Related]
3. Assisting PNA transport through cystic fibrosis human airway epithelia with biodegradable hybrid lipid-polymer nanoparticles.
Comegna M; Conte G; Falanga AP; Marzano M; Cernera G; Di Lullo AM; Amato F; Borbone N; D'Errico S; Ungaro F; d'Angelo I; Oliviero G; Castaldo G
Sci Rep; 2021 Mar; 11(1):6393. PubMed ID: 33737583
[TBL] [Abstract][Full Text] [Related]
4. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.
Zoulikha M; Xiao Q; Boafo GF; Sallam MA; Chen Z; He W
Acta Pharm Sin B; 2022 Feb; 12(2):600-620. PubMed ID: 34401226
[TBL] [Abstract][Full Text] [Related]
6. Tunable rigidity of PLGA shell-lipid core nanoparticles for enhanced pulmonary siRNA delivery in 2D and 3D lung cancer cell models.
Wang H; Yuan Y; Qin L; Yue M; Xue J; Cui Z; Zhan X; Gai J; Zhang X; Guan J; Mao S
J Control Release; 2024 Feb; 366():746-760. PubMed ID: 38237688
[TBL] [Abstract][Full Text] [Related]
7. Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung.
Tagalakis AD; Munye MM; Ivanova R; Chen H; Smith CM; Aldossary AM; Rosa LZ; Moulding D; Barnes JL; Kafetzis KN; Jones SA; Baines DL; Moss GWJ; O'Callaghan C; McAnulty RJ; Hart SL
Thorax; 2018 Sep; 73(9):847-856. PubMed ID: 29748250
[TBL] [Abstract][Full Text] [Related]
8. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
9. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier.
Di Gioia S; Trapani A; Castellani S; Carbone A; Belgiovine G; Craparo EF; Puglisi G; Cavallaro G; Trapani G; Conese M
Pulm Pharmacol Ther; 2015 Oct; 34():8-24. PubMed ID: 26192479
[TBL] [Abstract][Full Text] [Related]
10. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.
Suk JS; Kim AJ; Trehan K; Schneider CS; Cebotaru L; Woodward OM; Boylan NJ; Boyle MP; Lai SK; Guggino WB; Hanes J
J Control Release; 2014 Mar; 178():8-17. PubMed ID: 24440664
[TBL] [Abstract][Full Text] [Related]
11. Peptides as surface coatings of nanoparticles that penetrate human cystic fibrosis sputum and uniformly distribute in vivo following pulmonary delivery.
Leal J; Peng X; Liu X; Arasappan D; Wylie DC; Schwartz SH; Fullmer JJ; McWilliams BC; Smyth HDC; Ghosh D
J Control Release; 2020 Jun; 322():457-469. PubMed ID: 32243979
[TBL] [Abstract][Full Text] [Related]
12. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
Nafee N; Forier K; Braeckmans K; Schneider M
Eur J Pharm Biopharm; 2018 Mar; 124():125-137. PubMed ID: 29291931
[TBL] [Abstract][Full Text] [Related]
13. Mucus and Cell-Penetrating Nanoparticles Embedded in Nano-into-Micro Formulations for Pulmonary Delivery of Ivacaftor in Patients with Cystic Fibrosis.
Porsio B; Craparo EF; Mauro N; Giammona G; Cavallaro G
ACS Appl Mater Interfaces; 2018 Jan; 10(1):165-181. PubMed ID: 29235345
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration.
Thanki K; van Eetvelde D; Geyer A; Fraire J; Hendrix R; Van Eygen H; Putteman E; Sami H; de Souza Carvalho-Wodarz C; Franzyk H; Nielsen HM; Braeckmans K; Lehr CM; Ogris M; Foged C
J Control Release; 2019 Sep; 310():82-93. PubMed ID: 31398360
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary RNA interference against acute lung injury mediated by mucus- and cell-penetrating nanocomplexes.
Zhang W; Shen J; Liang J; Ge C; Zhou Y; Yin L; Ji Y
Acta Biomater; 2024 Mar; 177():332-346. PubMed ID: 38290689
[TBL] [Abstract][Full Text] [Related]
16. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.
Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J
Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138
[TBL] [Abstract][Full Text] [Related]
17. Dry powder aerosol containing muco-inert particles for excipient enhanced growth pulmonary drug delivery.
Chai G; Hassan A; Meng T; Lou L; Ma J; Simmers R; Zhou L; Rubin BK; Zhou QT; Longest PW; Hindle M; Xu Q
Nanomedicine; 2020 Oct; 29():102262. PubMed ID: 32623017
[TBL] [Abstract][Full Text] [Related]
18. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.
Gao LY; Liu XY; Chen CJ; Wang JC; Feng Q; Yu MZ; Ma XF; Pei XW; Niu YJ; Qiu C; Pang WH; Zhang Q
Biomaterials; 2014 Feb; 35(6):2066-78. PubMed ID: 24315577
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
Günday Türeli N; Torge A; Juntke J; Schwarz BC; Schneider-Daum N; Türeli AE; Lehr CM; Schneider M
Eur J Pharm Biopharm; 2017 Aug; 117():363-371. PubMed ID: 28476373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
